Characterisation of urogenital Neisseria gonorrhoeae isolates from microbiological failures in the phase II study
| Participant no. (sex) | GEP dose (mg) | Microbiological response | Visit | Mutation* | MIC (µg/mL)† | ||||||||||
| GyrA | ParC | GEP‡ | CIP | CRO | SPT | PEN | AZI§ | TET | CFM | ||||||
| 4 (male) | 3000 | Failure | Baseline | S91F | D95G | D86N | 1 | 8 | 0.06 | 8 | 4 | 0.5 | 2 | 0.06 | |
| TOC | S91F | A92T | D95G | D86N | >32 | 8 | 0.06 | 32 | 1 | 0.5 | 2 | 0.06 | |||
| 6 (male) | 3000 | Failure | Baseline | S91F | D95G | D86N | 1 | 4 | 0.06 | 16 | 1 | 0.5 | 2 | 0.06 | |
| TOC | S91F | A92T | D95G | D86N | 32 | 4 | 0.03 | 8 | 0.5 | 0.25 | 1 | 0.03 | |||
| 7 (male) | 1500 | Failure | Baseline | S91F | D95A | D86N | 1 | 16 | 0.03 | 8 | 2 | 2 | 2 | 0.03 | |
| TOC | S91F | D95A | D86N | 1 | 16 | 0.03 | 8 | 2 | 2 | 2 | 0.03 | ||||
Table reproduced with permission from Scangarella-Oman et al,21 under the Creative Commons Attribution License. Full terms at: https://creativecommons.org/licenses/by/4.0/.
*Sequencing of quinolone resistance–determining region only.
†Dark, light and no shading indicate resistant, intermediate and susceptible, respectively, according to M100-S27 CLSI breakpoints.
‡No breakpoints are currently available for GEP.
§The CLSI non-wild-type epidemiological cut-off value was applied.
AZI, azithromycin; CFM, cefixime; CIP, ciprofloxacin; CLSI, Clinical and Laboratory Standards Institute; CRO, ceftriaxone; GEP, gepotidacin; MIC, minimum inhibitory concentration; PEN, penicillin; SPT, spectinomycin; TET, tetracycline; TOC, test of cure.